RELAPSED NEUROBLASTOMA
Clinical trials for RELAPSED NEUROBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NEUROBLASTOMA trials appear
Sign up with your email to follow new studies for RELAPSED NEUROBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has come back or not responded to standard treatments. Participants first receive ch…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called GPC2 CAR T cells for children with advanced neuroblastoma or retinoblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and at…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Engineered immune cells take aim at childhood cancer in new trial
Disease control Recruiting nowThis study tests a new treatment for children and young adults with high-risk neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called ALK found o…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for kids with tough cancers: experimental drug PEEL-224 enters trials
Disease control Recruiting nowThis study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shr…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Theodore Laetsch • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Engineered immune cells take aim at stubborn childhood cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for children with neuroblastoma that has come back or is hard to treat. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells carrying a protein called PHOX2B. The main goal is to find a safe do…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Immune cell combo offers new hope for kids with resistant cancers
Disease control Recruiting nowThis study is for children with neuroblastoma or osteosarcoma that has come back or not responded to treatment. It tests a new approach: giving donor immune cells (gamma delta T cells) along with standard chemotherapy and an antibody drug. The main goal is to find the safest dose…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New hope for kids with Tough-to-Treat cancer: BEACON2 trial launches
Disease control Recruiting nowThis study is for children and young adults whose neuroblastoma has come back or not responded to standard treatment. It tests different combinations of drugs to see which works best and is safe. About 160 participants will receive one of three treatment plans, including targeted…
Matched conditions: RELAPSED NEUROBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated May 05, 2026 11:55 UTC